Migraine Market: Analysis of Epidemiology, Pipeline Therapies, and Key Companies Working in the market

October 11 19:50 2022
Migraine Market: Analysis of Epidemiology, Pipeline Therapies, and Key Companies Working in the market
Migraine Market:
DelveInsight’s ‘Migraine Market Insights, Epidemiology and Market Forecast—2032’ report delivers an in-depth understanding of the Migraine, historical and forecasted epidemiology as well as the market trends in the United States, the EU5 (Germany, Spain, Italy, France, and the United Kingdom) and Japan.

DelveInsight’s ‘Migraine Market Insights, Epidemiology and Market Forecast—2032’ report delivers an in-depth understanding of the Migraine, historical and forecasted epidemiology as well as the market trends in the United States, the EU5 (Germany, Spain, Italy, France, and the United Kingdom) and Japan.

 

The Migraine market report provides current treatment practices, emerging drugs, market share of individual therapies, and current and forecasted Migraine symptoms market size from 2019 to 2032 segmented by the seven major markets. The report also covers current Migraine symptoms treatment practice/algorithm, market drivers, market barriers, and unmet medical needs to curate the best of the opportunities and assesses the underlying potential of the market.

Some of the key facts of the Migraine Market:

  • According to a study by L J Stover et al. (2006), the proportion of adults in Europe reporting headaches was 51%, migraine 14%, and ‘chronic headache’ (i.e. > or =15 days/month or ‘daily’) 4%.
  • According to a study by F. Sakai et al., the overall prevalence of migraine in the past year was 8.4%; 5.8% was migraine without aura and 2.6% was migraine with aura. A significant correlation was found between the prevalence of migraine and such variables as gender, age and district of residence. 
  • According to a study by Lipton et al. (2007), the majority of migraineurs (62.7%) had 1 to 4 headache days per month. During migraine attacks, most migraineurs reported severe impairment or the need for bed rest (53.7%); just 7.2% reported no attack-related impairment..
  • According to DelveInsight’s’ estimates, the Migraine market in 7MM is expected to show good positive growth, during the forecast period (2019–2032), mainly attributed to huge list of upcoming product launches, robust pipeline of emerging therapies with novel MoA and different routes of administration. 

Got queries? Click here to know more about the Migraine market landscape

Migraine Overview

Migraine, a primary headache disorder, is a neurological condition that causes multiple symptoms frequently characterized by intense, debilitating headaches. It often runs in families and affects all ages. It is of majorly two types: acute and chronic migraine. The exact cause of migraine is unknown, but they are thought to be the result of abnormal brain activity temporarily affecting nerve signals, chemicals, and blood vessels in the brain. Many possible migraine triggers have been suggested, including hormonal, emotional, physical, dietary, environmental, and medicinal factors.  These triggers vary among individuals, but a diary may help keep track of consistent triggers.

With the first CGRP inhibitor approved in 2018, there have been many new approvals, offering a significant boost in migraine market growth. In September 2021, FDA approved QULIPTA  (atonement) for the preventive treatment of episodic migraine in adults. CGRP drugs (both oral and injectables) are proving to be revolutionary in the migraine market with huge advantages over traditional generic antidepressants, antihypertensives, etc. The migraine market size is anticipated to significantly grow during the study period, 2019–2032 owing to the robust pipeline of novel therapies like CGRP inhibitors, approval and launch of competitive products, increasing awareness to treat/prevent migraine,  increasing access due to improving reimbursements from payers. However, premium pricing of drugs, market access, and reimbursement challenges, are likely to complicate market success. Some of the therapies in the pipeline are, Zavegepant (Biohaven Pharmaceutical), AXS-07 (Axsome Therapeutics), and ABP-450 (AEON Biopharma) among others. 

Migraine Epidemiology Insights

  • According to NHS, migraine is a common health condition results in affecting around 1 in every 5 women and around 1 in every 15 men. It usually begins in early adulthood
  • A study by Burch R. et al, (2018) stated that results from the National Health Interview Survey (NHIS) show  that self-reported migraine and the severe headache was reported by 15.3% of Americans overall, including 9.7%  of men and 20.7% of women
  • According to Rebecca et al. (2019), migraine is common and occurs in about 12% of the US population overall, 18% of women, and 6% of men, each year.
  • According to the AMPP study, the prevalence of migraine in people aged 12 to 19 years is 6.3% (boys 5.0%, girls 7.7%). During adolescence, the prevalence in boys increases from 2.9% to 4.1%, and the prevalence in girls peaks at age 17 years at 9.8%.

 

Migraine Epidemiology Segmentation

 

  • Total migraine prevelant cases
  • Total migraine prevelant cases by severity
  • Total gender-specific migraine cases
  • Total diagnosed migraine cases

Migraine Market Outlook 

The Migraine market outlook of the report helps build a detailed comprehension of the historic, current, and forecasted Migraine market trends by analyzing the impact of current therapies on the market, unmet needs, drivers and barriers, and demand of better technology.

 

This segment gives a thorough detail of Migraine market trend of each marketed drug and late-stage pipeline therapy by evaluating their impact based on an annual cost of therapy, inclusion and exclusion criteria’s, mechanism of action, compliance rate, growing need of the market, increasing patient pool, covered patient segment, expected launch year, competition with other therapies, brand value, their impact on the market and view of the key opinion leaders. The calculated market data are presented with relevant tables and graphs to give a clear view of the market at first sight. According to DelveInsight, Migraine market in the 7MM is expected to change in the study period 2019-2032.

Learn more by requesting for sample @ Migraine Market

Migraine Key Companies 

  • Biohaven Pharmaceutical
  • Axsome Therapeutics
  • AEON Biopharma
  • And many more

 

Migraine  Therapies

 

  • Zavegepant
  • AXS-07
  • ABP-450
  • And many more

 

Table of Contents

  •  Key Insights 
  •  Report Introduction 
  •  Executive Summary of Migraine 
  •  Disease Background and Overview
  •  Epidemiology and patient population
  •  The United States 
  •  EU 5
  •  Migraine   Emerging Therapies
  •  Migraine Market Outlook
  •  Market Access and Reimbursement of Therapies
  •  Appendix
  •  Migraine Report Methodology
  •  DelveInsight Capabilities
  •  Disclaimer

Click here to read more about Migraine Market

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Adya Kaul
Email: Send Email
Phone: +91 9568243403
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com